Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoAdjuvant Dynamic marker-Adjusted Personalized Therapy (T-DXd vs standard neoadjuvant HER2 regimen in early HER2+ breast cancer)
2022-003865-39Phase 2Active
- Sponsor
- Westdeutsche Studiengruppe
- Start
- Jan 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of trastuzumab deruxtecan in breast cancer (3 arms), sponsored by Westdeutsche Studiengruppe. Primary endpoint: Pathologic complete response (pCR) after 12 or 18 weeks of neoadjuvant treatment. Started Jan 2023; status: active.
02
Drugs
trastuzumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2022-003865-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003865-39.